The Ministry of health of the Russian Federation issued a permit to conduct a clinical trial of the efficacy and safety of olokizumab (inhibitor of interleukin-6) and RPH-104 (inhibitor of interleukin-1) in the treatment of patients with severe infection COVID-19, reported the press service of “R-Pharm”.
Blocking interleukin-1 (IL-1) and interleukin-6 (IL-6) by means of biological drugs are used for pathogenetic therapy of a wide spectrum of hereditary autoinflammatory diseases, rheumatoid arthritis, giant cell arteritis, and cytokine storm.
The study will take place in the Institute of emergency care. N. In. Sklifosovsky Clinical hospital of infectious diseases them. S. P. Botkin in Saint-Petersburg city clinical hospital No. 40 in Kommunarka and city clinical hospital No. 52 in Moscow. Further studies will be connected and other Russian centers.
“Preliminary data from different countries indicate that the blocking of the immune hyperactivation in the levels of IL-1 or IL-6 may be effective in the treatment of patients with severe coronavirus infection, stabilize their condition, lead to further positive dynamics due to the suppression or prevention of cytokine storm,” – said the Director of the medical Department of “R-Pharm” Mikhail Samsonov.